News headlines about ChemoCentryx (NASDAQ:CCXI) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ChemoCentryx earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 60 out of 100, indicating that recent media coverage is somewhat likely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern’s rankings:
- ChemoCentryx, Inc. (CCXI) Given Hold Rating at Cowen and Company (americanbankingnews.com)
- ChemoCentryx Inc : Investor Network: Chemocentryx, Inc. to Host Earnings Call (4-traders.com)
- ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights (finance.yahoo.com)
- Reviewing ChemoCentryx (CCXI) and Auxilium Pharmaceuticals (AUXL) (americanbankingnews.com)
- ChemoCentryx, Inc. (NASDAQ:CCXI) Expected to Announce Earnings of -$0.19 Per Share (americanbankingnews.com)
Shares of ChemoCentryx (CCXI) opened at 10.14 on Wednesday. The company has a 50 day moving average of $9.47 and a 200 day moving average of $7.68. The company’s market cap is $488.47 million. ChemoCentryx has a 52 week low of $3.95 and a 52 week high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.14. The business had revenue of $8.23 million during the quarter. On average, analysts expect that ChemoCentryx will post ($0.69) EPS for the current year.
A number of analysts have weighed in on the stock. Cowen and Company reaffirmed a “hold” rating on shares of ChemoCentryx in a research note on Tuesday. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Monday, July 17th.
In related news, insider Petrus Bekker sold 65,509 shares of ChemoCentryx stock in a transaction on Friday, June 30th. The shares were sold at an average price of $9.17, for a total value of $600,717.53. Following the transaction, the insider now owns 89,839 shares in the company, valued at approximately $823,823.63. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last quarter, insiders sold 223,649 shares of company stock worth $2,157,360. 26.80% of the stock is owned by corporate insiders.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with our FREE daily email newsletter.